MS SB2751

Requires the Division of Medicaid to ensure that nonopioid drugs approved by the FDA for pain treatment or management are not disadvantaged or discouraged relative to opioid or narcotic drugs on the mandatory preferred drug list.

Prohibits designating nonopioid pain drugs as nonpreferred if any opioid or narcotic drug is preferred, and prevents more restrictive utilization controls (including prior authorization or step therapy) on nonopioid drugs than on opioids.

Applies these requirements to nonopioid drugs immediately upon FDA approval for pain treatment, regardless of division review status, and extends the requirements to managed care entity contracts.

Extends the repeal date of Section 43-13-117 from July 1, 2024 to July 1, 2027.

Effective July 1, 2024.